Endari Now More Accessible to Texas Medicaid Patients

Endari Now More Accessible to Texas Medicaid Patients

301949

Endari Now More Accessible to Texas Medicaid Patients

Endari (L-glutamine), an approved oral treatment for sickle cell disease (SCD), has now been added to the Preferred Drug List in Texas. The move will make Endari more accessible to people in the state who are insured through Medicaid, the government program that provides health insurance to low-income individuals, according to Emmaus Life Sciences, which markets the therapy. “With this recent revision, Texas joins many other states in improving access to Endari for the treatment…

You must be logged in to read/download the full post.